Sleep Apnea SyndromesScreenOXNCT03295149
ScreenOX - An Automated At-home Screening Test for Adult Sleep Apnea Using Nocturnal Oximetry
An observational study of Sleep Apnea Syndromes, run by Hospital del Rio Hortega at 1 site in Spain.
Trial summary
The sleep apnea-hypopnea syndrome (SAHS) is a respiratory disorder characterized by frequent breathing cessations (apneas) or partial collapses (hypopneas) during sleep. SAHS is linked with the most important causes of death in adults from industrialized countries. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sleep Apnea Syndromes
- How many people
- 400 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jan 2016to Dec 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive subjects derived to the sleep specialized outpatient facilities showing moderate-to-high clinical suspicion of suffering from SAHS due to at least one of the following symptoms: daytime hypersomnolence, loud snoring, nocturnal choking and awakenings, and/or apneic events reported by the subject or the bedmate.
Who may be able to join
- Men and women over 18 years old
- Subjects derived from primary care to the sleep specialized outpatient facilities showing moderate-to-high clinical suspicion of suffering from sleep apnea (daytime hypersomnolence, loud snoring, nocturnal choking and awakenings, and/or apneic events)
- Written informed consent signed
Who cannot join
- Subjects under 18 years old
- Subjects not signing the informed consent
- Presence of any previously diagnosed sleep disorder: narcolepsy, insomnia, chronic sleep deprivation, regular use of hypnotic or sedative medications and/or restless leg syndrome.
- Patients with the following chronic diseases: congestive heart failure, renal failure, neuromuscular diseases, chronic respiratory failure.
- Patients with >50% of central apneas or the presence of Cheyne-Stokes respiration.
- Previous continuous positive airway pressure (CPAP) treatment for SAHS diagnosis
- A medical history that may interfere with the study objectives or, in the opinion of the investigator, compromise the conclusions
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Río Hortega University Hospital
Valladolid, 47012
Félix Del Campo, PhD, MD, +34 983420400 ext. 85776, fsas@telefonica.net
Rosa Conde, +34 983420400 ext. 84400, rconvi@saludcastillayleon.es
About this study
Official title: New Out-of-center Paradigms to Simplify Sleep Apnea Diagnosis. Design and Development of an Automated Screening Test Based on Oximetry (ScreenOX)
The sleep apnea-hypopnea syndrome (SAHS) is a respiratory disorder characterized by frequent breathing cessations (apneas) or partial collapses (hypopneas) during sleep. SAHS is linked with the most important causes of death in adults from industrialized countries. Metabolic deregulation and cardiovascular and cerebrovascular diseases, such as atrial fibrillation, stroke, myocardial infarction and sudden cardiac death, could affect people having untreated SAHS. The gold standard method for SAHS diagnosis is in-hospital, technician-attended nocturnal polysomnography (PSG). Nevertheless, this methodology is labor-intensive, time-consuming, and relatively unavailable, especially in low-resource settings. These drawbacks have led to large waiting lists, which delay diagnosis and treatment and limits its effectiveness as single diagnostic method for SAHS. Blood oxygen saturation (SpO2) and pulse rate (PR) from nocturnal pulse oximetry (NPO) provide relevant and essential information to detect apneas. In addition, it is significantly less intrusive for patients and it can be easily recorded at patients' home. In the same way, automated signal processing and pattern recognition techniques have demonstrated to provide accurate tools able to detect and effectively use this information. Therefore, the investigators hypothesize that automated pattern recognition of at-home NPO recordings could provide reliable and efficient tools able to simplify the management of SAHS. The aim of this study is two-fold: 1) to prospectively assess the reliability and effectiveness of at-home NPO in the context of adult SAHS; 2) to design, optimize and extensively assess the diagnostic performance of automated NPO-based screening tools for SAHS. In order to achieve these goals, both PSG and NPO recordings are carried out ambulatory and simultaneously at patient's home. A portable polysomnograph (Embletta MPR, Natus) is used for standard PSG at home, whereas a portable wrist-worn pulse oximeter (WristOX2 3150, Nonin) is used for ambulatory NPO. In addition, conventional in-lab PSG and attended pulse oximetry are also performed simultaneously in the hospital facilities.
Read the detailed description
Participants are recruited from the specialized sleep outpatient facilities of the Río Hortega University Hospital from Valladolid (Spain). All patients are referred from primary care due to moderate-to-high clinical suspicion of suffering from sleep apnea-hypopnea syndrome (SAHS). The final population is randomly split into two independent datasets: 1) training set (50%), which is used to design and build/train the screening algorithms; and 2) the test set (remaining 50%), which is used to further assess performance using unseen data.
The American Academy of Sleep Medicine rules are used to score respiratory events and to obtain the apnea-hypopnea index (AHI) from ambulatory PSG at home, which is used to definitively diagnose SAHS.
A portable wrist-worn pulse oximeter (WristOX2 3150, Nonin) is used for at-home NPO. Portable NPO is carried out simultaneously to ambulatory PSG (Embletta MPR, Natus) at patient's home. In addition, attended portable in-lab NPO (WristOX2 3150, Nonin) and in-lab PSG (E-Series, Compumedics) are performed simultaneously in the hospital in a different consecutive/previous night for comparison purposes. Participants are randomly assigned to carry out unattended sleep studies at home before or after in-hospital recordings.
SpO2 and PR from NPO are recorded simultaneously at a sampling rate of 1 Hz (1 sample every second). All recordings are saved to separate files and processed offline. An automatic signal pre-processing stage is carried out to remove artifacts due to patient movements (signal loss).
The signal processing methodology is divided into three automated stages: (i) feature extraction, (ii) feature selection, and (iii) pattern recognition.
Firstly, NPO recordings are parameterized by means of a wide set of variables, which previously demonstrated a high discriminative power in the context of SAHS detection. All features are computed for each whole portable overnight recording. The following feature subsets are composed:
- Time domain statistics from SpO2 recordings. First to fourth-order statistical moments in the time domain, i.e., arithmetic mean, variance, skewness and kurtosis, which quantify central tendency, amount of dispersion, asymmetry, and peakedness, respectively.
- Time domain features from PR recordings: average, standard deviation, and root mean square of standard deviation of the pulse-to-pulse interval time series.
- Frequency domain statistics from SpO2 recordings. First to fourth-order statistical moments, median frequency, and Shannon spectral entropy from the power spectral density function.
- Frequency domain statistics from PR recordings. First to fourth-order statistical moments, median frequency, and Shannon spectral entropy from the power spectral density function.
- Conventional spectral measures from SpO2 recordings. Total signal power as well as peak amplitude and relative power in the frequency range 0.014 - 0.033 Hz.
- Conventional spectral measures from PR recordings. Normalized power in the low (0.04 - 0.15 Hz) and in the high (0.15 - 0.40 Hz) frequency bands, as well as the low frequency to high frequency ratio (sympathovagal balance).
- Nonlinear features from SpO2 recordings. Sample entropy, central tendency measure, and Lempel - Ziv complexity, which measure irregularity, variability, and complexity of SpO2 recordings.
- Nonlinear features from PR recordings. Sample entropy, central tendency measure, and Lempel - Ziv complexity, which measure irregularity, variability, and complexity of PR recordings.
Then, the optimum feature subset composed of the most relevant as well as complementary variables are composed. In order to achieve this goal, the following feature selection methods are applied:
- Forward stepwise feature selection
- Genetic algorithms
- Fast correlation-based filter
- Minimal-redundancy maximal-relevance criterion
Finally, the third stage corresponds to patter recognition. The aim of this stage is two-fold: (i) to design and optimize binary classification-oriented models trained to discern between SAHS negative and SAHS positive subjects using optimum features from NPO; (ii) to design and optimize regression-oriented models trained to estimate the AHI using optimum features from NPO. In order to achieve this goal, the following pattern recognition algorithms are assessed:
- Binary classification: logistic regression, artificial neural networks, Bayesian networks, decision trees, ensemble learning (AdaBoost).
- Regression models: multiple linear regression, artificial neural networks, Bayesian networks, ensemble learning (least squares boosting).
These models are subsequently combined to optimize the following 2-stage screening protocol: stage-1) true negative screening stage, which is aimed at detecting the maximum number of non-SAHS subjects while minimizing the number of false negative patients (ideally 0% false positive rate); stage-2) true positive screening stage, which is aimed at detecting (among patients not identified as true negative in the first stage) the maximum number of true positive patients while minimizing the number of false positive cases (ideally 0% false positive rate). Both stages are complementary and they are implemented consecutively, such that:
- Patients identified as true negative in the first stage are referred to the sleep specialist to finally discard SAHS taken into account symptoms, comorbidities and past clinical history. These patients are no longer derived to the sleep unit unless requested by the sleep specialist due to persistent and/or additional symptoms.
- Patients identified as true positive in the second stage are referred to the sleep specialist to finally confirm SAHS and decide the most suitable treatment option. These patients are no longer derived to the sleep unit unless requested by the sleep specialist.
- Non-conclusive cases are finally derived to the sleep unit for a standard PSG in order to confirm/discard SAHS.
- Conditions
- Sleep Apnea Syndromes
- Medical subject headings
- Sleep Apnea Syndromes
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients correctly classified
Percentage of patients (%) correctly classified/screened by the automated NPO-based screening test. At-home ambulatory PSG is used as the gold standard method for positive SAHS. Subjects with apnea-hypopnea index (AHI) <5 are considered no-SAHS subjects, with 5<=AHI<15 as mild SAHS patients, with 15<=AHI<30 moderate SAHS patients, and AHI>=30 as severe SAHS patients.
Measured: 6 months after the inclusion of the last patient
Secondary outcomes (28)
Body mass index
Average (median and interquartile range) body mass index (kg/m2) of the cohort.
Measured: 6 months after the inclusion of the last patient
Patients with chronic obstructive pulmonary disease
Number of patients (n) with comorbid chronic obstructive pulmonary disease (COPD), according to standard definitions.
Measured: 6 months after the inclusion of the last patient
Patients with hypertension
Number of patients (n) with comorbid arterial hypertension (HT), according to standard definitions.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived AHI
Apnea-hypopnea index (events per hour) derived from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived time in REM sleep
Percentage of time (%) in rapid eye movement (REM) sleep to the total sleep time derived from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived sleep efficiency
Sleep efficiency (%) measured as the percentage of total sleep time to the total recording time derived from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived arousal index
Number of arousals per hour of sleep (events per hour) derived from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived time in supine position
Percentage of time (%) in supine position to the total sleep time derived from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived average SpO2
Average overnight SpO2 (%) from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived minimum SpO2
Minimum overnight SpO2 (%) from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home PSG-derived oxygen desaturation index of 3% (ODI3)
Number of desaturations greater than or equal to 3% from baseline per hour of sleep (events per hor) from unattended PSG at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home NPO-derived ODI3
Number of desaturations greater than or equal to 3% from baseline per hour of recording (events per hor) from unattended pulse oximetry at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home NPO-derived cumulative time below 90% (CT90)
Percentage (%) of cumulative time with a saturation below 90% from unattended pulse oximetry at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home NPO-derived average SpO2
Average saturation (%) from unattended pulse oximetry at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home NPO-derived minimum SpO2
Minimum saturation (%) from unattended pulse oximetry at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home NPO-derived average pulse rate
Average pulse rate (beats per minute) from unattended pulse oximetry at patients' home.
Measured: 6 months after the inclusion of the last patient
At-home NPO-derived minimum pulse rate
Minimum pulse rate (beats per minute) from unattended pulse oximetry at patients' home.
Measured: 6 months after the inclusion of the last patient
Prevalence of SAHS
Prevalence of SAHS (%) in the population under study according to at-home PSG.
Measured: 6 months after the inclusion of the last patient
Severity of SAHS
Number of patients (n) with moderate-to-severe SAHS according to the at-home PSG-derived patient's AHI.
Measured: 6 months after the inclusion of the last patient
NPO-derived ODI3 agreement
Mean difference (mean +/- 1.96 standard deviation interval) from the Bland and Altman agreement plot between unattended ODI3 from at-home NPO and supervised ODI3 from in-hospital NPO.
Measured: 6 months after the inclusion of the last patient
PSG-derived AHI agreement
Mean difference (mean +/- 1.96 standard deviation interval) from the Bland and Altman agreement plot between unattended AHI from at-home PSG and supervised AHI from in-hospital PSG.
Measured: 6 months after the inclusion of the last patient
Optimum diagnostic performance - Area under the ROC curve
Area under the receiver operating characteristics (ROC) curve of the optimum NPO-based binary classifier compared to standard at-home PSG.
Measured: 6 months after the inclusion of the last patient
Optimum diagnostic performance - Accuracy
Accuracy (percentage, %) of the optimum NPO-based binary classifier compared to standard at-home PSG.
Measured: 6 months after the inclusion of the last patient
Optimum agreement - Intra-class correlation coefficient
Intra-class correlation coefficient (ICC) between the optimum NPO-based estimated AHI and the actual AHI derived from at-home PSG.
Measured: 6 months after the inclusion of the last patient
Patient's Sleep quality
Patients' sleep quality assessment using the Pittsburg questionnaire.
Measured: 6 months after the inclusion of the last patient
Patient's somnolence
Patients' somnolence assessment using the Epworth questionnaire.
Measured: 6 months after the inclusion of the last patient
Patients' quality of life
Patients' quality of life assessment using the Quebec sleep questionnaire (QSQ).
Measured: 6 months after the inclusion of the last patient
Percentage of unsatisfactory recordings
Number of recordings (n) removed from the study due to reasons (either technical or human) related to unattended portable oximetry.
Measured: 6 months after the inclusion of the last patient
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2017
- Study start1 Jan 2016
- Primary completionApr 2018 (estimated)
- Study completionDec 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sleep Apnea SyndromesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital del Rio Hortega
- Sponsor type
- University, hospital or other
- Collaborators
- OXIGEN salud, University of Valladolid, Five Flames Mobile
- Responsible party
- Principal investigator, Félix del Campo Matías, Hospital del Rio Hortega
- Investigators
- Félix Del Campo, PhD,MD, Principal investigator, Río Hortega University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03295149
- Sponsor's protocol ID
- RTC-2015-3446-1
- Acronym
- ScreenOX
- Status last verified
- Sep 2017
- First submitted
- 18 Sep 2017
- Last updated
- 2 Oct 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- New Out-of-center Paradigms to Simplify Sleep Apnea Diagnosis. Design and Development of an Automated Screening Test Based on Oximetry (ScreenOX)
- ClinicalTrials.gov ID
- NCT03295149
- Acronym / sponsor ID
- ScreenOX / RTC-2015-3446-1
- Conditions
- Sleep Apnea Syndromes
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Hospital del Rio HortegaUniversity, hospital or other
- Collaborators
- OXIGEN salud, University of Valladolid, Five Flames Mobile
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- Apr 2018 (estimated)
- Study completion
- Dec 2018 (estimated)
- First posted
- 27 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The sleep apnea-hypopnea syndrome (SAHS) is a respiratory disorder characterized by frequent breathing cessations (apneas) or partial collapses (hypopneas) during sleep. SAHS is linked with the most important causes of death in adults from industrialized countries. Metabolic deregulation and cardiovascular and cerebrovascular diseases, such as atrial fibrillation, stroke, myocardial infarction and sudden cardiac death, could affect people having untreated SAHS. The gold standard method for SAHS diagnosis is in-hospital, technician-attended nocturnal polysomnography (PSG). Nevertheless, this methodology is labor-intensive, time-consuming, and relatively unavailable, especially in low-resource settings. These drawbacks have led to large waiting lists, which delay diagnosis and treatment and limits its effectiveness as single diagnostic method for SAHS. Blood oxygen saturation (SpO2) and pulse rate (PR) from nocturnal pulse oximetry (NPO) provide relevant and essential information to detect apneas. In addition, it is significantly less intrusive for patients and it can be easily recorded at patients' home. In the same way, automated signal processing and pattern recognition techniques have demonstrated to provide accurate tools able to detect and effectively use this information. Therefore, the investigators hypothesize that automated pattern recognition of at-home NPO recordings could provide reliable and efficient tools able to simplify the management of SAHS. The aim of this study is two-fold: 1) to prospectively assess the reliability and effectiveness of at-home NPO in the context of adult SAHS; 2) to design, optimize and extensively assess the diagnostic performance of automated NPO-based screening tools for SAHS. In order to achieve these goals, both PSG and NPO recordings are carried out ambulatory and simultaneously at patient's home. A portable polysomnograph (Embletta MPR, Natus) is used for standard PSG at home, whereas a portable wrist-worn pulse oximeter (WristOX2 3150, Nonin) is used for ambulatory NPO. In addition, conventional in-lab PSG and attended pulse oximetry are also performed simultaneously in the hospital facilities.
Detailed description
Participants are recruited from the specialized sleep outpatient facilities of the Río Hortega University Hospital from Valladolid (Spain). All patients are referred from primary care due to moderate-to-high clinical suspicion of suffering from sleep apnea-hypopnea syndrome (SAHS). The final population is randomly split into two independent datasets: 1) training set (50%), which is used to design and build/train the screening algorithms; and 2) the test set (remaining 50%), which is used to further assess performance using unseen data.
The American Academy of Sleep Medicine rules are used to score respiratory events and to obtain the apnea-hypopnea index (AHI) from ambulatory PSG at home, which is used to definitively diagnose SAHS.
A portable wrist-worn pulse oximeter (WristOX2 3150, Nonin) is used for at-home NPO. Portable NPO is carried out simultaneously to ambulatory PSG (Embletta MPR, Natus) at patient's home. In addition, attended portable in-lab NPO (WristOX2 3150, Nonin) and in-lab PSG (E-Series, Compumedics) are performed simultaneously in the hospital in a different consecutive/previous night for comparison purposes. Participants are randomly assigned to carry out unattended sleep studies at home before or after in-hospital recordings.
SpO2 and PR from NPO are recorded simultaneously at a sampling rate of 1 Hz (1 sample every second). All recordings are saved to separate files and processed offline. An automatic signal pre-processing stage is carried out to remove artifacts due to patient movements (signal loss).
The signal processing methodology is divided into three automated stages: (i) feature extraction, (ii) feature selection, and (iii) pattern recognition.
Firstly, NPO recordings are parameterized by means of a wide set of variables, which previously demonstrated a high discriminative power in the context of SAHS detection. All features are computed for each whole portable overnight recording. The following feature subsets are composed:
- Time domain statistics from SpO2 recordings. First to fourth-order statistical moments in the time domain, i.e., arithmetic mean, variance, skewness and kurtosis, which quantify central tendency, amount of dispersion, asymmetry, and peakedness, respectively.
- Time domain features from PR recordings: average, standard deviation, and root mean square of standard deviation of the pulse-to-pulse interval time series.
- Frequency domain statistics from SpO2 recordings. First to fourth-order statistical moments, median frequency, and Shannon spectral entropy from the power spectral density function.
- Frequency domain statistics from PR recordings. First to fourth-order statistical moments, median frequency, and Shannon spectral entropy from the power spectral density function.
- Conventional spectral measures from SpO2 recordings. Total signal power as well as peak amplitude and relative power in the frequency range 0.014 - 0.033 Hz.
- Conventional spectral measures from PR recordings. Normalized power in the low (0.04 - 0.15 Hz) and in the high (0.15 - 0.40 Hz) frequency bands, as well as the low frequency to high frequency ratio (sympathovagal balance).
- Nonlinear features from SpO2 recordings. Sample entropy, central tendency measure, and Lempel - Ziv complexity, which measure irregularity, variability, and complexity of SpO2 recordings.
- Nonlinear features from PR recordings. Sample entropy, central tendency measure, and Lempel - Ziv complexity, which measure irregularity, variability, and complexity of PR recordings.
Then, the optimum feature subset composed of the most relevant as well as complementary variables are composed. In order to achieve this goal, the following feature selection methods are applied:
- Forward stepwise feature selection
- Genetic algorithms
- Fast correlation-based filter
- Minimal-redundancy maximal-relevance criterion
Finally, the third stage corresponds to patter recognition. The aim of this stage is two-fold: (i) to design and optimize binary classification-oriented models trained to discern between SAHS negative and SAHS positive subjects using optimum features from NPO; (ii) to design and optimize regression-oriented models trained to estimate the AHI using optimum features from NPO. In order to achieve this goal, the following pattern recognition algorithms are assessed:
- Binary classification: logistic regression, artificial neural networks, Bayesian networks, decision trees, ensemble learning (AdaBoost).
- Regression models: multiple linear regression, artificial neural networks, Bayesian networks, ensemble learning (least squares boosting).
These models are subsequently combined to optimize the following 2-stage screening protocol: stage-1) true negative screening stage, which is aimed at detecting the maximum number of non-SAHS subjects while minimizing the number of false negative patients (ideally 0% false positive rate); stage-2) true positive screening stage, which is aimed at detecting (among patients not identified as true negative in the first stage) the maximum number of true positive patients while minimizing the number of false positive cases (ideally 0% false positive rate). Both stages are complementary and they are implemented consecutively, such that:
- Patients identified as true negative in the first stage are referred to the sleep specialist to finally discard SAHS taken into account symptoms, comorbidities and past clinical history. These patients are no longer derived to the sleep unit unless requested by the sleep specialist due to persistent and/or additional symptoms.
- Patients identified as true positive in the second stage are referred to the sleep specialist to finally confirm SAHS and decide the most suitable treatment option. These patients are no longer derived to the sleep unit unless requested by the sleep specialist.
- Non-conclusive cases are finally derived to the sleep unit for a standard PSG in order to confirm/discard SAHS.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive subjects derived to the sleep specialized outpatient facilities showing moderate-to-high clinical suspicion of suffering from SAHS due to at least one of the following symptoms: daytime hypersomnolence, loud snoring, nocturnal choking and awakenings, and/or apneic events reported by the subject or the bedmate.
Key inclusion criteria (3 listed)
- Men and women over 18 years old
- Subjects derived from primary care to the sleep specialized outpatient facilities showing moderate-to-high clinical suspicion of suffering from sleep apnea (daytime hypersomnolence, loud snoring, nocturnal choking and awakenings, and/or apneic events)
- Written informed consent signed
Key exclusion criteria (7 listed)
- Subjects under 18 years old
- Subjects not signing the informed consent
- Presence of any previously diagnosed sleep disorder: narcolepsy, insomnia, chronic sleep deprivation, regular use of hypnotic or sedative medications and/or restless leg syndrome.
- Patients with the following chronic diseases: congestive heart failure, renal failure, neuromuscular diseases, chronic respiratory failure.
- Patients with >50% of central apneas or the presence of Cheyne-Stokes respiration.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of patients correctly classified
Time frame: 6 months after the inclusion of the last patient
Percentage of patients (%) correctly classified/screened by the automated NPO-based screening test. At-home ambulatory PSG is used as the gold standard method for positive SAHS. Subjects with apnea-hypopnea index (AHI) <5 are considered no-SAHS subjects, with 5<=AHI<15 as mild SAHS patients, with 15<=AHI<30 moderate SAHS patients, and AHI>=30 as severe SAHS patients.
28 secondary outcomes
Body mass index
Time frame: 6 months after the inclusion of the last patient
Patients with chronic obstructive pulmonary disease
Time frame: 6 months after the inclusion of the last patient
Patients with hypertension
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived AHI
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived time in REM sleep
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived sleep efficiency
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived arousal index
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived time in supine position
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived average SpO2
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived minimum SpO2
Time frame: 6 months after the inclusion of the last patient
At-home PSG-derived oxygen desaturation index of 3% (ODI3)
Time frame: 6 months after the inclusion of the last patient
At-home NPO-derived ODI3
Time frame: 6 months after the inclusion of the last patient
At-home NPO-derived cumulative time below 90% (CT90)
Time frame: 6 months after the inclusion of the last patient
At-home NPO-derived average SpO2
Time frame: 6 months after the inclusion of the last patient
At-home NPO-derived minimum SpO2
Time frame: 6 months after the inclusion of the last patient
At-home NPO-derived average pulse rate
Time frame: 6 months after the inclusion of the last patient
At-home NPO-derived minimum pulse rate
Time frame: 6 months after the inclusion of the last patient
Prevalence of SAHS
Time frame: 6 months after the inclusion of the last patient
Severity of SAHS
Time frame: 6 months after the inclusion of the last patient
NPO-derived ODI3 agreement
Time frame: 6 months after the inclusion of the last patient
PSG-derived AHI agreement
Time frame: 6 months after the inclusion of the last patient
Optimum diagnostic performance - Area under the ROC curve
Time frame: 6 months after the inclusion of the last patient
Optimum diagnostic performance - Accuracy
Time frame: 6 months after the inclusion of the last patient
Optimum agreement - Intra-class correlation coefficient
Time frame: 6 months after the inclusion of the last patient
Patient's Sleep quality
Time frame: 6 months after the inclusion of the last patient
Patient's somnolence
Time frame: 6 months after the inclusion of the last patient
Patients' quality of life
Time frame: 6 months after the inclusion of the last patient
Percentage of unsatisfactory recordings
Time frame: 6 months after the inclusion of the last patient
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2017.
- Web of the Rio Hortega University Hospital, SpainLink provided by the sponsor.
- Web of OXIGEN salud. Respiratory therapy provider, SpainLink provided by the sponsor.
- Web of the Biomedical Engineering Group (GIB), University of Valladolid, SpainLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Sleep Apnea Syndromes
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Recruiting
Janus II Feasibility
Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Félix Del Campo, PhD,MD principal investigator
Río Hortega University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sleep Apnea Syndromes, run by Hospital del Rio Hortega at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Félix Del Campo, PhD, MD (+34 983420400 ext. 85776, fsas@telefonica.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients correctly classified (time frame: 6 months after the inclusion of the last patient). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2017.